Earnings Report

The cosmetics company’s restructuring program wipes out around half of its quarterly profit.

Bristol Myers Squibb issues an especially upbeat outlook for 2026, even as revenue is expected to fall within one product portfolio.

The pharmaceutical distributor and health services company raises its guidance for the second time.

Earnings weren’t good enough to assuage private credit concerns.

The oil company's earnings fell in the fourth quarter, and so did the stock Thursday.

Align, which makes the Invisalign teeth-straightening system, beat analysts’ estimates for quarterly earnings and revenue.

The connected-fitness company posts a wider-than-expected loss and a decline in revenue in its fiscal second quarter.

Investors have come to expect a lot from the retailer. Its latest boost to its financial guidance just wasn’t enough to satisfy Wall Street.

All eyes are on the sales and expense growth at Google Cloud.

The company also raised its guidance for the full year.

Snap said it’s making a “strategic pivot toward profitable growth.”

Wall Street expected earnings of 41 cents a share, on revenue of $1.23 billion, according to FactSet.

Qualcomm forecast lower than expected revenue for the current quarter.

GE HealthCare reported fourth-quarter earnings per share of $1.44 from sales of $5.7 billion. Wall Street was looking for earnings per share of $1.40 from sales of $5.6 billion.

Mercury Systems reported earnings per share of 16 cents. Wall Street was looking for 7 cents.

The cosmetics company’s revenue jumped nearly 40% from last year in the holiday quarter, helping drive a top- and bottom-line beat.

SMCI shares have been struggling, but the onetime artificial-intelligence darling’s latest results could ease some concerns.

Eli Lilly reports fourth-quarter earnings and revenue that handily top expectations and issues solid guidance.

AbbVie posts better-than-expected earnings but revenue declines across certain business lines.

The ride-hailing company posts 19% growth in revenue but adjusted earnings fall well short of Wall Street estimates.

The company’s BetMGM joint venture reports strong revenue and earnings growth in the fourth quarter.

The Swiss bank says it is poised to regain momentum in its U.S. wealth business.

The Ozempic and Wegovy maker reports full-year sales of 309.1 billion Danish krone, beating analysts’ forecasts.

Private-credit stocks have been weighed down by worries over their loans to software firms. Investors are anxious to learn the latest on their loan portfolios.

Raymond James analyst Andrew Marok raised his price target on Take-Two.